Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL5763517

COc1cc2c(CNS(=O)(=O)C(F)(F)F)cnc(C(=O)c3cccc(OC(C)C)c3)c2cc1OC.O=C(O)C(F)(F)F

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFPT1 Q06210 1/20 0.95
VNN1 O95497 3/20 0.36
DPP4 P27487 1/20 0.36
KAT6A Q92794 2/20 0.35
F2 P00734 1/20 0.35
PDGFRB P09619 2/20 0.35
APAF1 O14727 1/20 0.35
NSD2 O96028 1/20 0.35
CASP3 P42574 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MET P08581 1/20 0.34
MAPT P10636 2/20 0.34
TP53 P04637 2/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
FLT4 P35916 1/20 0.34
MCHR1 Q99705 1/20 0.34
KDR P35968 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5809762 0.97 GFPT1 (1.00) GFPT1VNN1KAT6APDGFRBAPAF1
Trifluoroacetic Acid SCHEMBL6106759 0.93 GFPT1 (0.81) GFPT1VNN1DPP4KAT6AF2
SCHEMBL6106939 0.90 GFPT1 (0.86) GFPT1VNN1KAT6APDGFRBAPAF1
Trifluoroacetic Acid SCHEMBL6108973 0.87 GFPT1 (0.73) GFPT1VNN1DPP4PDGFRBMET
SCHEMBL6109152 0.87 GFPT1 (0.81) GFPT1VNN1KAT6APDGFRBAPAF1
Trifluoroacetic Acid SCHEMBL6108469 0.85 GFPT1 (0.70) GFPT1DPP4PTGDR2
Trifluoroacetic Acid SCHEMBL5768365 0.85 GFPT1 (0.70) GFPT1VNN1DPP4APAF1NSD2
SCHEMBL6109830 0.85 GFPT1 (0.77) GFPT1VNN1KAT6APDGFRBAPAF1
SCHEMBL6108765 0.85 GFPT1 (0.77) GFPT1VNN1PDGFRBMETFLT4
Hydrochloric Acid SCHEMBL6110105 0.84 GFPT1 (0.76) GFPT1VNN1KAT6APDGFRBAPAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067529-B2 Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors HOFFMANN-LA ROCHE INC. (US) 2006-06-27 US disclosed
EP-1631551-A2 ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2006-03-08 EP disclosed
US-20040259910-A1 Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors BOLIN DAVID ROBERT (US) 2004-12-23 US disclosed
WO-2004101528-A2 ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259910-A1 Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors GFPT1, GLS2, GLS GFPT1 1/4885VNN1 2430/4885DPP4 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.